How Fructose Contributes To Obesity
A new preclinical study demonstrates how fructose can alter cells in the small intestine, increasing nutrient absorption and promoting weight gain. In addition, the research indicates that excessive fructose consumption, such as drinks sweetened with high-fructose corn syrup (HFCS), enhances the body’s ability to absorb dietary fats.
The new study builds on a 2019 examination of the effect HFCS has on colorectal cancer. That examination discovered a molecular mechanism by which fructose boosts tumor cell growth. Therefore, the succeeding study targeted the impact of fructose on non-cancerous intestinal cells.
Millions of minuscule, hairlike protrusions called villi are lining our small intestines. Villi, among many functions, absorb nutrients from food. The first finding in the new research, published in the journal Nature, was that mice fed high-fructose diets had 40% longer villi than animals not fed fructose. Further investigation revealed that mice with these longer villi gained more weight on a high-fat diet than those fed without added fructose.
What’s more, the researchers detected high levels of fructose-1-phosphate, a metabolite of fructose, building up in cells. Fructose-1-phosphate can increase the survival of villus cells. It is precisely this mechanism that the researchers suggest is responsible for fructose-promoting villi length, resulting in increased fat absorption and weight gain.
Samuel Taylor, the study’s first author, hypothesizes an evolutionary explanation for animals developing this mechanism, adding that it’s understandable for hibernating mammals to maximize fat absorption from fructose in fruit.
Taylor noted:
“In mammals, especially hibernating mammals in temperate climates, you have fructose being very available in the fall months when the fruit is ripe. So eating a lot of fructose may help these animals to absorb and convert more nutrients to fat, which they need to get through the winter.”
However, the problem that arises with humans is the overconsumption of fructose in sweeteners like high-fructose corn syrup. “Fructose itself is not harmful. It’s a problem of overconsumption. Our bodies were not designed to eat as much of it as we do,” explained senior author Marcus DeSilva Goncalves.

This isn’t the first study on the potential damage caused by the overconsumption of fructose. For example, a 2019 study looked at the influence of a high fructose diet on the body and found that consuming elevated levels of fructose inhibits the liver’s ability to metabolize fat properly, resulting in more significant accumulations of fat. However, this effect was not seen with glucose.
While the new study needs more investigation before the findings are confirmed in humans, Goncalves is confident that the results could potentially lead to new methods for treating obesity and colorectal cancers once validated in humans.
Goncalves explained:
“There are already drugs in clinical trials for other purposes that target the enzyme responsible for producing fructose-1-phosphate. We’re hoping to find a way to repurpose them to shrink the villi, reduce fat absorption, and possibly slow tumor growth.”
Anti-Obesity Drug
A new anti-obesity drug, currently moving toward clinical trials, could help reduce obesity by neutralizing asprosin with monoclonal antibodies to break the cycle of appetite and weight gain.
Scientists at Ohio’s Harrington Discovery Institute at University Hospitals in Cleveland investigated the connection between metabolic syndrome and an essential hormone. They demonstrated how a new drug could play a significant preventative role in various conditions.
While experiments were carried out in mice, the researchers are optimistic about the drug’s potential in humans. The novel drug could suppress appetite and blood glucose and prevent obesity and diabetes. The research focused on a hormone called asprosin, which the team had previously discovered plays a regulatory role in appetite and glucose and insulin levels in the blood.
Earlier experiments revealed that people with lower asprosin levels experienced decreased levels of hunger and that, on the contrary, its levels were far higher in those suffering from metabolic syndrome, conditions including high blood pressure, obesity, and insulin resistance that combine to increase the risk of stroke, heart disease, and diabetes.

Atul Chopra, a senior author on the study, said:
“In 2016, we discovered a hormone called asprosin, which stimulates appetite and increases blood glucose levels by acting on the hypothalamus and the liver. Unfortunately, for unclear reasons, asprosin levels are elevated in patients with metabolic syndrome, leading to even higher appetite, body weight, and blood glucose. We found that we can break that disease cycle by neutralizing asprosin with monoclonal antibodies.”
As part of the new research published in the journal eLife, three different mouse models with metabolic syndrome were used to test monoclonal antibodies to inhibit asprosin. The scientists found that the treated mice displayed reduced appetite, body weight, and blood glucose levels.
Dr. Mishra explained:
“When mice were treated with monoclonal antibodies that neutralize asprosin, they ate less, lost weight, and their blood glucose levels normalized. Elevated appetite, body weight, and blood glucose are three critical features of metabolic syndrome, and they were all corrected with these antibody treatments.”

Chopra said:
“We already know what happens to humans when asprosin is low. That’s a very privileged situation in biomedical science because of the confidence it creates for drug development. Many drugs succeed in mice but fail in humans. In this case, knowing that humans with low asprosin have reduced appetite, body weight, and blood glucose and insulin is tremendously helpful at designing and developing drugs to mimic this beneficial effect in patients with metabolic syndrome.”
The scientists eye potential therapeutic use with the monoclonal antibodies in the future. But first, they will need to adapt the drug for use in humans, which will involve determining the ideal dosage to limit unwanted effects.
Chopra concluded:
“Progress towards clinical trials and making the drug ready for humans is the last piece of the puzzle. We want to keep the dose of the drug low and don’t want side effects. While we know this concept and this drug works, our next step in the process is to make it better and ready for humans.”
Interestingly, being overweight has some benefits, but not many. Therefore, ultimately, it’s healthier to be fit than overweight.
The “Obesity Paradox”
Over 15 years ago, scientists noticed something unexpected among patients undergoing CKD treatment for chronic kidney disease. Across various studies, overweight or mildly obese patients displayed more excellent survival rates than those with a healthy weight. The phenomenon became known as the “obesity paradox,” leaving scientists puzzled at what could be causing it.
A recent study published in Cell Metabolism adds further weight to the hypothesis of an obesity paradox, finding correlations between obesity and short-term protection against cardiovascular disease. This obesity paradox remains a mystery, but now researchers at the University of Texas Southwestern Medical Center (UTSW) have uncovered one possible mechanism behind it.

Fat tissue typically stores extra calories as lipids, but metabolic stress can result in this tissue becoming dysfunctional over time. Therefore, lipids are more likely to build up in organs like the liver, heart, or kidneys, causing a condition called lipotoxicity that can bring various health problems. However, oddly enough, lipotoxicity doesn’t have a concrete relationship with obesity – some even argue that obesity can protect against that damage, at least temporarily.
The UTSW team tested the phenomenon in mice that were engineered so that their fat tissue would become dysfunctional faster, then fed them a high-fat diet. The researchers found that the fat cells give off a “distress signal” when they become dysfunctional, which the heart subsequently responds to with a lasting and robust defense.

An indicator of dysfunctional fat tissue is that the mitochondria (the energy-producing structures within cells) shrink and die off. The team discovered that fragments of these dying mitochondria were released into the animals’ bloodstream. Once these fragments reach the heart, they activate oxidative stress, which damages organs. As a result, heart cells generate antioxidant molecules to protect the organs from damage.
That powerful protection may play a vital role in the obesity paradox. The researchers tested its potency by injecting mice with molecules containing dying mitochondrial, then inducing a heart attack. The results showed that the mice that got the injections had considerably less damage to the organ than mice that didn’t receive the doses. “The mechanism we have identified here could be one of many that protect the heart in obesity,” explained Philipp Scherer, the study’s lead author.
Follow-up examinations checked for signs of this process in human patients. In addition, the UTSW team analyzed fat tissue samples from obese patients and found that they were also releasing particles comprising dying mitochondria, meaning it could potentially be adapted into a treatment to prevent heart damage. “By better understanding the distress signal from fat, we may be able to harness the mechanism to improve heart health in obese and non-obese individuals alike,” concluded Dr. Clair Crewe, the study’s co-lead author.
